Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

ABBOTT LABORATORIES : Change in Directors or Principal Officers (form 8-K)

11/20/2020 | 04:09pm EST

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers



As previously reported, Abbott has Agreements Regarding Change in Control ("Agreements") with its named executive officers, other than Miles D. White, Abbott's Executive Chairman, who is not party to an Agreement.

The Agreements provide that if Abbott gives notification of extension before the Expiration Date (December 31, 2020), the Agreement's term shall continue through the second anniversary of the Expiration Date.

On November 20, 2020, Abbott notified the named executive officers who are party to the Agreements that the term of the Agreements was extended through December 31, 2022.

© Edgar Online, source Glimpses

All news about ABBOTT LABORATORIES
06:37aABBOTT LABORATORIES : Receives expanded medicare reimbursement for first-of-its-..
AQ
01/20ABBOTT LABORATORIES : Says MitraClip Device to Receive Expanded Medicare Reimbur..
MT
01/20ABBOTT : Receives Expanded Medicare Reimbursement for First-Of-Its-Kind MitraCli..
PR
01/15ABBOTT LABORATORIES : To launch the neurosphere mypath digital health app design..
AQ
01/14ABBOTT : to Launch the NeuroSphere™ myPath™ Digital Health App Desig..
PR
01/14ABBOTT LABORATORIES : Ex-dividend day for
FA
01/13ABBOTT LABORATORIES : Announces fulfillment of federal government purchase of 15..
AQ
01/12ABBOTT LABORATORIES : Fulfills US Government's Order of 150 Million BinaxNOW COV..
MT
01/12ABBOTT : Announces Fulfillment of Federal Government Purchase of 150 Million Bin..
PR
01/11ABBOTT LABORATORIES : Receives FDA 510(k) Clearance for Rapid Handheld Blood Tes..
MT
More news
Financials (USD)
Sales 2020 33 854 M - -
Net income 2020 4 415 M - -
Net Debt 2020 11 794 M - -
P/E ratio 2020 46,1x
Yield 2020 1,28%
Capitalization 194 B 194 B -
EV / Sales 2020 6,06x
EV / Sales 2021 5,26x
Nbr of Employees 107 000
Free-Float 88,9%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | MarketScreener
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 119,94 $
Last Close Price 112,95 $
Spread / Highest target 19,5%
Spread / Average Target 6,19%
Spread / Lowest Target -27,4%
EPS Revisions
Managers and Directors
NameTitle
Robert B. Ford President, CEO, Chief Operating Officer & Director
Miles D. White Executive Chairman
Robert E. Funck Chief Financial Officer & Executive Vice President
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES3.11%193 426
MEDTRONIC PLC1.84%160 567
BECTON, DICKINSON AND COMPANY5.23%76 581
HOYA CORPORATION-5.57%48 658
ALIGN TECHNOLOGY, INC.5.61%44 501
BAXTER INTERNATIONAL INC.-0.90%40 620